Morphological and biochemical studies on liver biopsies of parkinsonian patients treated with levodopa and decarboxylase inhibitor.
D000135:Acid Phosphatase / Q000032:analysis; D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000032:analysis; D000626:Aminopeptidases / Q000032:analysis; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001706:Biopsy; D002214:Capsules; D002403:Cathepsins / Q000032:analysis; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005952:Glucose-6-Phosphatase / Q000032:analysis; D005966:Glucuronidase / Q000032:analysis; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000473:pathology*; D008297:Male; D008854:Microscopy, Electron; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002214:Capsules; D004338:Drug Combinations; D004295:Dihydroxyphenylalanine; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D005952:Glucose-6-Phosphatase; D005966:Glucuronidase; D002403:Cathepsins; D000626:Aminopeptidases; D004296:Dopa Decarboxylase